Integra LifeSciences (NASDAQ:IART) Issues Earnings Results

Integra LifeSciences (NASDAQ:IART) released its quarterly earnings results on Monday. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.02), Zacks reports. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $382.65 million for the quarter, compared to analysts’ expectations of $381.17 million. During the same quarter in the prior year, the company posted $0.55 earnings per share. The business’s revenue for the quarter was up 3.7% compared to the same quarter last year. Integra LifeSciences updated its Q2 2025 guidance to 0.400-0.450 EPS and its FY 2025 guidance to 2.190-2.290 EPS.

Integra LifeSciences Trading Down 21.2 %

Shares of IART stock opened at $13.28 on Tuesday. The stock has a market capitalization of $1.03 billion, a P/E ratio of -147.54, a price-to-earnings-growth ratio of 0.73 and a beta of 1.27. Integra LifeSciences has a fifty-two week low of $11.60 and a fifty-two week high of $32.66. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company has a 50 day moving average price of $19.73 and a 200 day moving average price of $22.09.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IART. Truist Financial reduced their price target on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research note on Friday, April 11th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus target price of $22.71.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.